CN106214801A - 一种精神科护理上用于安神的药物组合物 - Google Patents
一种精神科护理上用于安神的药物组合物 Download PDFInfo
- Publication number
- CN106214801A CN106214801A CN201610703822.5A CN201610703822A CN106214801A CN 106214801 A CN106214801 A CN 106214801A CN 201610703822 A CN201610703822 A CN 201610703822A CN 106214801 A CN106214801 A CN 106214801A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- soothing nerves
- psychiatric nursing
- psychiatric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 37
- 230000000474 nursing effect Effects 0.000 title claims abstract description 35
- 210000005036 nerve Anatomy 0.000 title claims abstract description 27
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims abstract description 38
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims abstract description 36
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims abstract description 19
- 241001672694 Citrus reticulata Species 0.000 claims abstract description 19
- 239000005770 Eugenol Substances 0.000 claims abstract description 19
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims abstract description 19
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims abstract description 19
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims abstract description 19
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims abstract description 19
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960002173 citrulline Drugs 0.000 claims abstract description 19
- 235000013477 citrulline Nutrition 0.000 claims abstract description 19
- 229960002217 eugenol Drugs 0.000 claims abstract description 19
- 239000003722 gum benzoin Substances 0.000 claims abstract description 19
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims abstract description 19
- 229960000365 meptazinol Drugs 0.000 claims abstract description 19
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960003495 thiamine Drugs 0.000 claims abstract description 19
- 235000019157 thiamine Nutrition 0.000 claims abstract description 19
- 239000011721 thiamine Substances 0.000 claims abstract description 19
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims abstract description 18
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims abstract description 18
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 18
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960002327 chloral hydrate Drugs 0.000 claims abstract description 18
- 229960003291 chlorphenamine Drugs 0.000 claims abstract description 18
- WPFVBOQKRVRMJB-UHFFFAOYSA-N hydroxycitronellal Chemical compound O=CCC(C)CCCC(C)(C)O WPFVBOQKRVRMJB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229930007744 linalool Natural products 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 18
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims abstract description 17
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims abstract description 17
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims abstract description 17
- 229940106189 ceramide Drugs 0.000 claims abstract description 17
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims abstract description 17
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 abstract description 2
- 230000002936 tranquilizing effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 13
- 208000028017 Psychotic disease Diseases 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- -1 acyl Amine Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000013312 nursing technique Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003339 pneumostatic effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004577 thatch Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种精神科护理上用于安神的药物组合物，按重量组份计，主要是由以下成分组成：硫胺素1‑4份、甲氮卓酚0.2‑1份、安息香树脂1‑5份、柑油2‑4.5份、羟基香茅醛0.3‑1份、芳樟醇1.2‑3.5份、水合氯醛0.05‑0.1份、氯苯那敏0.2‑0.8份、丁香酚0.1‑0.3份、神经酰胺0.2‑0.4份、瓜氨酸2‑7份、α‑氨基丁酸1‑5份、氢化卵磷脂1‑3.2份。本发明药物组合物对于精神科患者有很好的镇静安神效果，在精神科疾病的护理方面有突出的疗效，且没有明显的副作用，有效促进患者康复。
Description
技术领域
本发明涉及精神科疾病护理技术领域，具体是涉及一种精神科护理上用于安神的药物组合物。
背景技术
精神病是由于人体内外各种有害因素引起的大脑功能紊乱，导致知觉、意识、情感、思维、行为和智能等障碍的一类疾病，特点是心理状态的异常，表现为各种各样的精神症状。精神病常见类型包括精神分裂症、狂躁抑郁性精神病、更年期精神病、偏执性精神病及各种器质性病变伴发的精神病等。往往会有抑郁的情绪，或是极度兴奋，或是常常焦虑失眠。
患上精神病后人们最关心的就是如何更好的治疗精神病，目前随着不断发展的医学技术和逐渐丰富的临床经验，对精神病患者的保健和护理也越来越重视。对精神病患者来说，一定要做到安神静气，很多人患上精神病的原因都和自己的情绪或是心理状况因素是分不开的。失眠是大多数精神病患者最常见的症状，具体表现为入睡困难、睡而易醒、醒后不能再睡、晨醒过早、时睡时醒或整夜不能入睡。顽固的失眠症常使患者非常痛苦，如不能有效的治疗，会严重影响患者的身心健康、工作和学习。因此，十分有必要开发一种精神科护理上用于安神的药物组合物。
发明内容
本发明解决的技术问题是提供一种精神科护理上用于安神的药物组合物。
本发明的技术方案是：一种精神科护理上用于安神的药物组合物，按重量组份计，主要是由以下成分组成：硫胺素1-4份、甲氮卓酚0.2-1份、安息香树脂1-5份、柑油2-4.5份、羟基香茅醛0.3-1份、芳樟醇1.2-3.5份、水合氯醛0.05-0.1份、氯苯那敏0.2-0.8份、丁香酚0.1-0.3份、神经酰胺0.2-0.4份、瓜氨酸2-7份、α-氨基丁酸1-5份、氢化卵磷脂1-3.2份。
优选配比为：硫胺素1.5-3.5份、甲氮卓酚0.4-0.8份、安息香树脂2-4份、柑油2.5-4.0份、羟基香茅醛0.4-0.9份、芳樟醇1.7-3.0份、水合氯醛0.06-0.09份、氯苯那敏0.3-0.7份、丁香酚0.15-0.25份、神经酰胺0.25-0.35份、瓜氨酸3-6份、α-氨基丁酸1.5-4.5份、氢化卵磷脂1.4-2.8份。
优选配比为：硫胺素2.5份、甲氮卓酚0.6份、安息香树脂3份、柑油3.25份、羟基香茅醛0.65份、芳樟醇2.35份、水合氯醛0.075份、氯苯那敏0.5份、丁香酚0.2份、神经酰胺0.3份、瓜氨酸4.5份、α-氨基丁酸3份、氢化卵磷脂2.1份。
一种精神科护理上用于安神的药物组合物，其制备方法为：按所述配比称取硫胺素、甲氮卓酚、安息香树脂、柑油、羟基香茅醛、芳樟醇、水合氯醛、氯苯那敏、丁香酚、神经酰胺、瓜氨酸、α-氨基丁酸、氢化卵磷脂，混合均匀，即得到所述精神科护理上用于安神的药物组合物。
进一步地，将所述药物组合物按照药学常规制药方法及辅料要求制备成药学上可接受的口服制剂。
进一步地，所述口服制剂包括但不限于片剂、胶囊剂、颗粒剂。
更进一步地，所述片剂的制备方法为：在所述药物组合物中加入22～35份淀粉糖浆、7～12份蔗糖、0.2～0.5份微晶纤维，制粒，压制成片，包衣制成片剂。
更进一步地，所述胶囊剂的制备方法为：在所述药物组合物中加入25～45份预胶化淀粉、0.1～0.5份β-环糊精，0.2～0.4份硬脂酸镁，制粒，装胶囊，制成硬胶囊剂。
更进一步地，所述颗粒剂的制备方法为：在所述药物组合物中加入40～70份蔗糖和4～7份糊精，混匀，制成颗粒并干燥，即得颗粒剂。
本发明的有益效果是：本发明药物组合物对于精神科患者有很好的镇静安神效果，在精神科疾病的护理方面有突出的疗效，且没有明显的副作用，有效促进患者康复。
具体实施方式
实施例1:
一种精神科护理上用于安神的药物组合物，按重量组份计，主要是由以下成分组成：硫胺素1份、甲氮卓酚0.2份、安息香树脂1份、柑油2份、羟基香茅醛0.3份、芳樟醇1.2份、水合氯醛0.05份、氯苯那敏0.2份、丁香酚0.1份、神经酰胺0.2份、瓜氨酸2份、α-氨基丁酸1份、氢化卵磷脂1份。
该精神科护理上用于安神的药物组合物的制备方法为：按所述配比称取硫胺素、甲氮卓酚、安息香树脂、柑油、羟基香茅醛、芳樟醇、水合氯醛、氯苯那敏、丁香酚、神经酰胺、瓜氨酸、α-氨基丁酸、氢化卵磷脂，混合均匀，即得到所述精神科护理上用于安神的药物组合物。
将所述药物组合物按照药学常规制药方法及辅料要求制备成片剂：在所述药物组合物中加入22份淀粉糖浆、7份蔗糖、0.2份微晶纤维，制粒，压制成片，包衣制成片剂。
实施例2:
一种精神科护理上用于安神的药物组合物，按重量组份计，主要是由以下成分组成：硫胺素1.5份、甲氮卓酚0.4份、安息香树脂2份、柑油2.5份、羟基香茅醛0.4份、芳樟醇1.7份、水合氯醛0.06份、氯苯那敏0.3份、丁香酚0.15份、神经酰胺0.25份、瓜氨酸3份、α-氨基丁酸1.5份、氢化卵磷脂1.4份。
该精神科护理上用于安神的药物组合物的制备方法为：按所述配比称取硫胺素、甲氮卓酚、安息香树脂、柑油、羟基香茅醛、芳樟醇、水合氯醛、氯苯那敏、丁香酚、神经酰胺、瓜氨酸、α-氨基丁酸、氢化卵磷脂，混合均匀，即得到所述精神科护理上用于安神的药物组合物。
将所述药物组合物按照药学常规制药方法及辅料要求制备成胶囊剂：在所述药物组合物中加入25份预胶化淀粉、0.1份β-环糊精，0.2份硬脂酸镁，制粒，装胶囊，制成硬胶囊剂。
实施例3:
一种精神科护理上用于安神的药物组合物，按重量组份计，主要是由以下成分组成：硫胺素2.5份、甲氮卓酚0.6份、安息香树脂3份、柑油3.25份、羟基香茅醛0.65份、芳樟醇2.35份、水合氯醛0.075份、氯苯那敏0.5份、丁香酚0.2份、神经酰胺0.3份、瓜氨酸4.5份、α-氨基丁酸3份、氢化卵磷脂2.1份。
该精神科护理上用于安神的药物组合物的制备方法为：按所述配比称取硫胺素、甲氮卓酚、安息香树脂、柑油、羟基香茅醛、芳樟醇、水合氯醛、氯苯那敏、丁香酚、神经酰胺、瓜氨酸、α-氨基丁酸、氢化卵磷脂，混合均匀，即得到所述精神科护理上用于安神的药物组合物。
将所述药物组合物按照药学常规制药方法及辅料要求制备成颗粒剂：在所述药物组合物中加入55份蔗糖和5.5份糊精，混匀，制成颗粒并干燥，即得颗粒剂。
实施例4:
一种精神科护理上用于安神的药物组合物，按重量组份计，主要是由以下成分组成：硫胺素3.5份、甲氮卓酚0.8份、安息香树脂4份、柑油4.0份、羟基香茅醛0.9份、芳樟醇3.0份、水合氯醛0.09份、氯苯那敏0.7份、丁香酚0.25份、神经酰胺0.35份、瓜氨酸6份、α-氨基丁酸4.5份、氢化卵磷脂2.8份。
该精神科护理上用于安神的药物组合物的制备方法为：按所述配比称取硫胺素、甲氮卓酚、安息香树脂、柑油、羟基香茅醛、芳樟醇、水合氯醛、氯苯那敏、丁香酚、神经酰胺、瓜氨酸、α-氨基丁酸、氢化卵磷脂，混合均匀，即得到所述精神科护理上用于安神的药物组合物。
将所述药物组合物按照药学常规制药方法及辅料要求制备成胶囊剂：在所述药物组合物中加入45份预胶化淀粉、0.5份β-环糊精，0.4份硬脂酸镁，制粒，装胶囊，制成硬胶囊剂。
实施例5:
一种精神科护理上用于安神的药物组合物，按重量组份计，主要是由以下成分组成：硫胺素4份、甲氮卓酚1份、安息香树脂5份、柑油4.5份、羟基香茅醛1份、芳樟醇3.5份、水合氯醛0.1份、氯苯那敏0.8份、丁香酚0.3份、神经酰胺0.4份、瓜氨酸7份、α-氨基丁酸5份、氢化卵磷脂3.2份。
该精神科护理上用于安神的药物组合物的制备方法为：按所述配比称取硫胺素、甲氮卓酚、安息香树脂、柑油、羟基香茅醛、芳樟醇、水合氯醛、氯苯那敏、丁香酚、神经酰胺、瓜氨酸、α-氨基丁酸、氢化卵磷脂，混合均匀，即得到所述精神科护理上用于安神的药物组合物。
将所述药物组合物按照药学常规制药方法及辅料要求制备成片剂：在所述药物组合物中加入35份淀粉糖浆、12份蔗糖、0.5份微晶纤维，制粒，压制成片，包衣制成片剂。
临床验证：
1.对象选择：选择182名患者，均为精神科焦虑失眠患者，其中，男102例，平均年龄35.3±0.4岁；女80例，平均年龄41.5±0.5岁。随机平分为2组，每组91人，两组患者无显著差异。
2、治疗方法：治疗组：服用实施例3制备的颗粒剂，一日3次，每次6g，连续30日。对照组：口服地西泮(天津力生制药)5mg/日，连续30日。
3、结果：治疗组和对照组分别经过上述方法进行治疗后，治疗组共有74名患者症状有改善，有效率为(74/91)81.3％；对照组仅有23名患者症状有所改善，有效率为(23/91)25.3％；这说明本发明药物用于临床上精神科患者安神护理的药物效果显著。
最后应说明的是：以上实施例仅用以说明本发明的技术方案，而非对其限制；尽管参照前述实施例对本发明进行了详细的说明，本领域的普通技术人员应当理解：其依然可以对前述实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本发明实施例技术方案的精神和范围。
Claims (6)
1.一种精神科护理上用于安神的药物组合物，其特征在于，按重量组份计，主要是由以下成分组成：硫胺素1-4份、甲氮卓酚0.2-1份、安息香树脂1-5份、柑油2-4.5份、羟基香茅醛0.3-1份、芳樟醇1.2-3.5份、水合氯醛0.05-0.1份、氯苯那敏0.2-0.8份、丁香酚0.1-0.3份、神经酰胺0.2-0.4份、瓜氨酸2-7份、α-氨基丁酸1-5份、氢化卵磷脂1-3.2份。
2.如权利要求1所述的一种精神科护理上用于安神的药物组合物，其特征在于，按重量组份计，主要是由以下成分组成：硫胺素1.5-3.5份、甲氮卓酚0.4-0.8份、安息香树脂2-4份、柑油2.5-4.0份、羟基香茅醛0.4-0.9份、芳樟醇1.7-3.0份、水合氯醛0.06-0.09份、氯苯那敏0.3-0.7份、丁香酚0.15-0.25份、神经酰胺0.25-0.35份、瓜氨酸3-6份、α-氨基丁酸1.5-4.5份、氢化卵磷脂1.4-2.8份。
3.如权利要求1所述的一种精神科护理上用于安神的药物组合物，其特征在于，按重量组份计，主要是由以下成分组成：硫胺素2.5份、甲氮卓酚0.6份、安息香树脂3份、柑油3.25份、羟基香茅醛0.65份、芳樟醇2.35份、水合氯醛0.075份、氯苯那敏0.5份、丁香酚0.2份、神经酰胺0.3份、瓜氨酸4.5份、α-氨基丁酸3份、氢化卵磷脂2.1份。
4.如权利要求1-3任意一项所述的一种精神科护理上用于安神的药物组合物，其特征在于，制备方法为：按所述配比称取硫胺素、甲氮卓酚、安息香树脂、柑油、羟基香茅醛、芳樟醇、水合氯醛、氯苯那敏、丁香酚、神经酰胺、瓜氨酸、α-氨基丁酸、氢化卵磷脂，混合均匀，即得到所述精神科护理上用于安神的药物组合物。
5.如权利要求4所述的一种精神科护理上用于安神的药物组合物的制备方法，其特征在于，将所述药物组合物按照药学常规制药方法及辅料要求制备成药学上可接受的口服制剂。
6.如权利要求5所述的一种精神科护理上用于安神的药物组合物的制备方法，其特征在于，所述口服制剂包括但不限于片剂、胶囊剂、颗粒剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610703822.5A CN106214801A (zh) | 2016-08-22 | 2016-08-22 | 一种精神科护理上用于安神的药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610703822.5A CN106214801A (zh) | 2016-08-22 | 2016-08-22 | 一种精神科护理上用于安神的药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106214801A true CN106214801A (zh) | 2016-12-14 |
Family
ID=57552782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610703822.5A Pending CN106214801A (zh) | 2016-08-22 | 2016-08-22 | 一种精神科护理上用于安神的药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106214801A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107669933A (zh) * | 2017-11-09 | 2018-02-09 | 徐莉 | 一种精神科护理上用于安神的药物组合物及其制备方法 |
| WO2020239052A1 (zh) * | 2019-05-30 | 2020-12-03 | 特丰制药有限公司 | 含有水合氯醛的药盒及其用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1379678A (zh) * | 1999-10-01 | 2002-11-13 | 强生消费者公司 | 用个人护理组合物镇静人类的方法 |
-
2016
- 2016-08-22 CN CN201610703822.5A patent/CN106214801A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1379678A (zh) * | 1999-10-01 | 2002-11-13 | 强生消费者公司 | 用个人护理组合物镇静人类的方法 |
Non-Patent Citations (4)
| Title |
|---|
| 刘克辛主编: "《临床药理学》", 31 January 2012, 清华大学出版社 * |
| 张明编著: "《食物相宜与相克大百科》", 30 June 2013, 天津科学技术出版社 * |
| 马世昌主编: "《化学物质辞典》", 30 April 1999, 陕西科学技术出版社 * |
| 黄峻，黄祖瑚主编: "《临床药物手册 第5版》", 31 March 2003, 山东科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107669933A (zh) * | 2017-11-09 | 2018-02-09 | 徐莉 | 一种精神科护理上用于安神的药物组合物及其制备方法 |
| WO2020239052A1 (zh) * | 2019-05-30 | 2020-12-03 | 特丰制药有限公司 | 含有水合氯醛的药盒及其用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101874891B (zh) | 一种治疗心悸的中药组合物及其制备方法 | |
| CN101810800A (zh) | 一种治疗皮肤瘙痒的中药组合物及其制备方法 | |
| CN102764340A (zh) | 一种改善睡眠的中药组合物及其制备方法和应用 | |
| CN101816771B (zh) | 一种治疗癫痫病的中药组合物及其制备方法 | |
| CN104873745A (zh) | 一种治疗失眠的中药及制备方法 | |
| CN102614407B (zh) | 一种治疗产后抑郁症的中药组合物 | |
| CN102973561A (zh) | 一种用于改善睡眠的药物组合物及其制备方法 | |
| CN106214801A (zh) | 一种精神科护理上用于安神的药物组合物 | |
| CN107296863A (zh) | 一种治疗老年痴呆的药物 | |
| CN101810787B (zh) | 一种治疗心烦的中药组合物及其制备方法 | |
| CN100425279C (zh) | 一种治疗癫痫的药物 | |
| CN104248722A (zh) | 一种用于治疗女性性欲亢进的药物 | |
| CN103239625B (zh) | 一种治疗面神经麻痹症的中药制剂 | |
| CN104223073A (zh) | 一种助眠的食品、保健品或药物组合物 | |
| CN102908396B (zh) | 一种具有促进睡眠作用的中药组合物及其制备方法 | |
| CN101543587A (zh) | 用以治疗多发性抽动症的中草药复方及应用其药学组成物 | |
| CN101773628A (zh) | 一种治疗呃逆病的中药组合物及其制备方法 | |
| CN102114149B (zh) | 治疗癫痫病的中药制剂 | |
| WO2021012065A1 (zh) | 一种牛黄清心丸在制备治疗抑郁症的药物中的应用 | |
| CN112641911A (zh) | 一种快速治疗遗尿与早泄的药物 | |
| CN103736019B (zh) | 一种治疗失眠多梦的中药制剂 | |
| CN106511752A (zh) | 一种治疗青年焦虑性失眠的中药组合物 | |
| CN105796946A (zh) | 一种治疗失眠的中药制剂 | |
| CN102885539B (zh) | 一种缓解小儿夜惊的药枕 | |
| CN107837331A (zh) | 一种治疗失眠的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161214 |